Brain natriuretic peptide as a predictor of sudden cardiac death in patients with myocardial infarction  by Rashidi, Arash & Adler, Dale S.
sive changes such as interstitial fibrosis would advance our
understanding of the relevant mechanisms.
Dr. O’Rourke makes the important point that systolic
pressure measured at the brachial artery is significantly
influenced by wave reflection, and that central aortic pres-
sure is a more important influence on LV systolic function.
Central aortic pressure is influenced by arterial stiffness (2),
but our preliminary findings are that, while arterial compli-
ance (measured using the pulse pressure method using radial
artery tonometry) was less in patients with a hypertensive
response to exercise compared with controls (3), it was not
related to indices of LV systolic function. Moreover, work
in progress suggests that augmentation index using carotid
tonometry is no different in those with a hypertensive
response to exercise and control subjects. Thus, although we
agree with Dr. O’Rourke that measurement of LV ejection
duration or estimation of aortic systolic pressure during
exercise may provide insight into the mechanism of a
hypertensive response to exercise as recorded with cuff blood
pressure at the upper limb, our preliminary data do not
support a major association of LV systolic dysfunction with
central hemodynamics.
Philip M. Mottram, MBBS, FRACP
Thomas H. Marwick, MBBS, PhD, FACC
University of Queensland
Department of Medicine
Princess Alexandra Hospital
Ipswich Road
Brisbane Q4102
Australia
E-mail: tmarwick@soms.uq.edu.au
doi:10.1016/j.jacc.2004.07.011
REFERENCES
1. Mottram PM, Haluska B, Yuda S, Leano R, Marwick TH. Patients
with a hypertensive response to exercise have impaired systolic function
without diastolic dysfunction or left ventricular hypertrophy. J Am Coll
Cardiol 2004;43:848–53.
2. O’Rourke M. Arterial stiffness, systolic blood pressure, and logical
treatment of arterial hypertension. Hypertension 1990;15:339–47.
3. Mottram PM, Haluska BA, Leano R, Yuda S, Marwick TH. Patients
with a hypertensive response to exercise have impaired systolic function
and reduced arterial compliance (abstr). Circulation 2002;106:II422.
Brain Natriuretic Peptide as a
Predictor of Sudden Cardiac Death
in Patients With Myocardial Infarction
We read with interest the study by Tapanainen et al. (1).
The researchers introduced the brain natriuretic peptide
(BNP) as a good predictor of sudden cardiac death
(SCD) after acute myocardial infarction (AMI). In their
study, BNP level of the patients with AMI was used to
predict SCD. The incidence of SCD after the mean
follow-up of 43  13 months was 3.1%. The mean BNP
level in patients with SCD was 54.4  76.1 pmol/l and
it was 26.1  28.0 pmol/l in survivors. They found that
a BNP level of 23.0 pmol/l was the best cut-off point to
predict SCD. In another new study by Wang et al. (2),
higher BNP was also associated with increased risk of
overall death. The investigators reported a 27% increase
in the risk of death with each increment of 1 SD in log
of BNP level.
We know from the Multicenter Automatic Defibrillator
Implantation Trial II (MADIT II) investigators that the
survival of postmyocardial infarction patients with ejection
fraction (EF)30% will improve with prophylactic implan-
tation of a defibrillator (3). It means that irrespective of
BNP level, post-AMI patients with low EF will derive
benefit from defibrillator implantation. Approximately one-
third of the patients with prior infarction, left ventricular EF
40%, and spontaneous nonsustained ventricular tachycar-
dia (VT) have inducible sustained VT, predicting 6% to 9%
per year risk of sustained VT or SCD. A defibrillator
reduces this risk to 3% to 5% per year (3,4). An EF between
30% to 40% is a gray area for defibrillator implantation, and
this is the area that needs more clarification.
The studies have shown that BNP can probably be a good
predictor of death, especially SCD, after MI. If we know the
value of this predictive role in post-myocardial infarction
patients with EF between 30% and 40%, we may be able to
use it as a guide to defibrillator implantation decision. In the
study by Tapanainen et al. (1) the mean EF of patients with
SCD was 39.9  10.8%. It seems that most of the patients
in the study had an EF 30%, but separate analyses for
different EF levels were not shown. We believe that if the
researchers could perform a separate analysis for the patients
with EF between 30% and 40%, the role of BNP level in
predicting SCD in non-MADIT II patients might be more
clearly established.
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REPLY
The question of clinical utility of measurement of plasma
brain natriuretic peptide (BNP) after an acute myocardial
infarction (AMI), raised by Drs. Rashidi and Adler, is most
pertinent and relevant. Indeed, a simple measurement of
BNP from the blood sample might have clinical importance
in estimation of candidacy for implantable cardioverter-
defibrillator (ICD) therapy. We would like to add a few
more comments to the issue of risk stratification of patients
after an AMI and of potential clinical utility of BNP
measurement.
The post hoc analysis of the Multicenter Automatic
Defibrillator Implantation Trial II (MADIT II) investiga-
tors showed that patients with a recent AMI (18 months)
did not have a mortality benefit from the ICD therapy (1).
Similar preliminary data were presented at the American
College of Cardiology meeting in March 2004 (unpub-
lished) from the Defibrillator In Acute Myocardial Infarc-
tion Trial (DINAMIT), where ICD therapy did not reduce
all-cause mortality among the patients with a recent AMI
(ejection fraction [EF] 0.35) and reduced heart rate
variability. Therefore, evaluation of the candidacy for ICD
therapy shortly after an AMI is still a challenge and an
obvious field for further research.
Our study showed that patients with a low plasma BNP
level, measured at the convalescent phase after an AMI,
have an extremely low incidence of sudden cardiac death
(SCD) (2). Our main implication is that the measurement
of BNP can be used to identify the “low-risk” patients who
may not need further risk stratification and may not benefit
from prophylactic ICD despite depressed left ventricular
function. For example, there were no SCDs among the
patients with an EF 0.35 and low BPN (23.0 pmol/l)
during the follow-up. Also, BNP did not reach statistical
significance in prediction of SCD among patients with an
EF between 0.30 and 0.40. However, elevated BNP had a
better predictive power among those with preserved left
ventricular function (EF 0.40) (relative risk 3.9; 95%
confidence interval 1.0 to 16.5; p  0.05). Patients with an
EF 0.40 also constituted the highest cumulative number
of SCD events. Prediction and prevention of SCD among
the large number of survivors of AMI who have a preserved
left ventricular function will be important in future efforts
aimed at reducing the overall burden of premature SCD.
Measurement of BNP may have clinical value in this
respect.
In conclusion, we believe measurement of BNP at the
convalescent phase after an AMI is most suitable for
excluding patients at risk for future SCD. Evaluation of the
candidacy for ICD therapy shortly after an AMI still
remains a challenge both for scientists and clinicians.
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Does Nondipping Blood Pressure
Profile Contribute to Vascular
Inflammation During Sleep Deprivation?
We read with great interest the study by Meier-Ewert et al.
(1) describing elevated high sensitivity C-reactive protein
(hs-CRP) in healthy subjects after both acute total and
partial sleep deprivation. The investigators hypothesized
that such low-grade inflammation associated with sleep loss
might contribute to the increased cardiovascular risk de-
scribed in sleep complaints.
As far as the mechanisms responsible for such increment
of circulating hs-CRP levels after sleep deprivation, the
researchers suggest a role for vascular shear stress exacer-
bated by increased blood pressure (BP) levels (1). In this
context, a trend toward an increment of systolic and
diastolic BP was observed during both total and partial sleep
deprivation. However, only changes of systolic BP across
total sleep deprivation achieved statistical significance. In
addition, circulating hs-CRP levels significantly increased,
starting with the first day of total sleep deprivation, despite
irrelevant changes of systolic and diastolic BP. Thus, sleep
deprivation-related increments of BP do not completely
explain the interesting findings by Meier-Ewert et al. (1).
In this regard, sleep disturbances strongly affect both
nighttime blood pressure levels and the nocturnal BP drop
in healthy subjects as well as in hypertensive patients (2).
The blunted nocturnal decline in BP, also known as
“nondipping profile,” has been reported to be associated
with increased vascular damage, at least in hypertensive
patients (3). In keeping with this, a nondipping profile has
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